XTX Topco Ltd Purchases 94,943 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

XTX Topco Ltd increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 720.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,120 shares of the biotechnology company's stock after purchasing an additional 94,943 shares during the period. XTX Topco Ltd owned 0.22% of REGENXBIO worth $836,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Barclays PLC grew its position in shares of REGENXBIO by 9.5% during the fourth quarter. Barclays PLC now owns 127,065 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 11,041 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of REGENXBIO during the fourth quarter valued at approximately $568,000. Renaissance Technologies LLC bought a new stake in shares of REGENXBIO during the fourth quarter valued at approximately $2,097,000. Aristides Capital LLC bought a new position in shares of REGENXBIO during the fourth quarter worth $187,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in REGENXBIO during the fourth quarter valued at $79,000. Institutional investors own 88.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RGNX shares. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Raymond James initiated coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target on the stock. Morgan Stanley lifted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Finally, HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, REGENXBIO has an average rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Trading Up 9.3 %

Shares of NASDAQ RGNX traded up $0.62 during midday trading on Tuesday, hitting $7.29. The company's stock had a trading volume of 380,973 shares, compared to its average volume of 803,285. The business's 50 day moving average is $6.80 and its two-hundred day moving average is $8.11. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $17.52. The firm has a market cap of $365.50 million, a P/E ratio of -1.44 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. On average, analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.